Quintero RA, Rozo EJ, Acosta CA, Vargas LJ, Lizarazo DN, Restrepo MP

Language: Spanish
References: 20
Page: 64-70
PDF size: 207.25 Kb.

ABSTRACT

Background: Congenital erythropoietic porphyria, or Günther’s disease, is a nonacute cutaneous porphyria that is characterized as a rare autosomal recessive disorder, currently approximately 200 cases have been reported in the world with a prevalence of 0.9 per 1,000,000 habitants.
Clinical case: A 38-year-old female patient who consulted for a 12-hour clinical presentation of epigastralgia associated with hematemesis and multiple diarrheal episodes without mucus; additionally she presented dyspnea, cough, edema and thickening of the skin that predominated in the legs, spontaneous ulceration of the skin of the hands and face. History of hirsutism, virilization, and sclerodactyly. On physical examination she had icteric scleras, subconjunctival hemorrhages, atrophic scars on the nasal dorsum and accentuation of barcode lines, erythrodontia, jugular engorgement, occasional rales on the right base, sclerodactyly, calcinosis in hands and face, marked hirsutism, ichthyosis in the lower limbs, lenticular macules, deformity on the back of the hands and pigmentary changes on the outside of the forearms. The paraclinic studies confirmed the diagnosis of congenital erythropoietic porphyria.
Conclusions: Congenital erythropoietic porphyria is an infrequent disease, which occurs mainly in people with a family history, and is due to a deficiency of the enzyme uroporphyrinogen III. The most relevant clinical manifestations are cutaneous photosensitivity, erythrodontia, corneal lesion, chronic hemolytic anemia, and changes in the color of the urine from pink to dark red.

REFERENCES

1. Phillips JD. Heme biosynthesis and the porphyrias. MolGenet Metab 2019; 128 (3): 164-77. doi: 10.1016/j.ymgme. 2019.04.008.

2. Szlendak U, Bykowska K, Lipniacka A. Clinical, biochemicaland molecular characteristics of the main types ofporphyria. Adv Clin Exp Med 2016;; 25 (2): 361-8. doi:10.17219/acem/58955.

3. Erwin AL, Desnick RJ. Congenital erythropoietic porphyria:Recent advances. Mol Genet Metab 2019; 128 (3): 288-297.doi: 10.1016/j.ymgme.2018.12.008.

4. Kahila A, Zamlout A, Mazloum A, Laila O, Badran A. Congenitalerythropoietic porphyria (Gunther disease): a casereport. Oxf Med Case Reports 2020; 2020 (7): 227-30. doi:10.1093/omcr/omaa051.

5. Howard M, Hall A, Ramsay D. Congenital erythropoieticporphyria (Gunther disease) – Long-term follow up of acase and review. Dermatol Online J 2017; 23 (2).

6. Garg KK, Singh H. A case of congenital erythropoietic porphyriawithout haemolysis. Eur J Case Reports Intern Med2016; 3 (7). doi: 10.12890/2016_000497.

7. Frusciante V, Ferrari C, Totaro M, Valle G, Guida CC, AucellaF, et al. Brain perfusion defects by SPET/CT and neurostatsemi-quantitative analysis in two patients with congenitalerythropoietic porphyria. Hell J Nucl Med 2018; 21 (1):43-7.

8. Di Pierro E, Brancaleoni V, Granata F. Advances in understandingthe pathogenesis of congenital erythropoieticporphyria. Br J Haematol 2016; 173 (3): 365-79. doi:10.1111/bjh.13978.

9. Lee WH, Tai WC, Wu PY. Congenital erythropoietic porphyria.Dermatologica Sin 2012; 30 (2): 62-5. https://doi.org/10.1016/j.dsi.2011.09.012.

10. Sandal S, Puri RD. Congenital erythropoietic porphyria: Acase report and approach to cutaneous porphyrias. GeneticClinics 2019; 2-5.

11. Shirazi N, Chauhan P, Jindal R, Ahmad S. Congenital erythropoieticporphyria: A rare case of photosensitivity with hemolyticanaemia and mental retardation. J Coll Physicians SurgPak 2019; 29 (6): S23-5. doi: 10.29271/jcpsp.2019.06.S23.

12. Stölzel U, Doss MO, Schuppan D. Clinical guide and updateon porphyrias. Gastroenterology 2019; 157 (2): 365-381.e4. doi: 10.1053/j.gastro.2019.04.050.

13. Dawe R. An overview of the cutaneous porphyrias.F1000Research. 2017; 6 (0): 1-11. doi: 10.12688/f1000research.10101.1.

14. Edel Y, Mamet R. Porphyria: What is it and who should beevaluated? Rambam Maimonides Med J 2018; 9 (2): e0013.Disponible en: doi: 10.5041/RMMJ.10333.

15. Rigor J, Pinto SA, Martins-Mendes D. Porphyrias: A clinicallybased approach. Eur J Intern Med 2019; 67: 24-9. doi:10.1016/j.ejim.2019.06.014.

16. Besnard C, Schmitt C, Galmiche-Rolland L, Debray D,Fabre M, Molina T, et al. Bone marrow transplantation incongenital erythropoietic porphyria: sustained efficacy butunexpected liver dysfunction. Biol Blood Marrow 2020; 26(4): 704-11. doi: 10.1016/j.bbmt.2019.12.005.

17. Blouin JM, Bernardo-Seisdedos G, Sasso E, Esteve J, Ged C,Lalanne M, et al. Missense UROS mutations causing congenitalerythropoietic porphyria reduce UROS homeostasisthat can be rescued by proteasome inhibition. Hum MolGenet 2017; 26 (8): 1565-76. doi: 10.1093/hmg/ddx067.

18. Yasuda M, Desnick RJ. Murine models of the humanporphyrias: Contributions toward understanding diseasepathogenesis and the development of new therapies.Mol Genet Metab 2019; 128 (3): 332-41. doi: 10.1016/j.ymgme.2019.01.007.

19. Urquiza P, Laín A, Sanz-Parra A, Moreno J, Bernardo-Seisdedos G, Dubus P, et al. Repurposing ciclopirox asa pharmacological chaperone in a model of congenitalerythropoietic porphyria. Sci Transl Med 2018; 10 (459).doi: 10.1126/scitranslmed.aat7467.

20. Blouin J-M, Ged C, Lalanne M, Lamrissi-Garcia I, Morice-Picard F, Costet P, et al. Iron chelation rescues hemolyticanemia and skin photosensitivity in congenital erythropoieticporphyria. Blood. 2020; 136 (21): 2457-2468. doi:10.1182/blood.2020006037.